256 related articles for article (PubMed ID: 22370532)
1. Immunoglobulin E monitoring and reduction of omalizumab therapy in children and adolescents.
Steiss JO; Schmidt A; Nährlich L; Zimmer KP; Rudloff S
Allergy Asthma Proc; 2012; 33(1):77-81. PubMed ID: 22370532
[TBL] [Abstract][Full Text] [Related]
2. Reduction of the total IgE level by omalizumab in children and adolescents.
Steiss JO; Strohner P; Zimmer KP; Lindemann H
J Asthma; 2008 Apr; 45(3):233-6. PubMed ID: 18415832
[TBL] [Abstract][Full Text] [Related]
3. Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma.
Özgür ES; Özge C; Ïlvan A; Naycı SA
J Asthma; 2013 Aug; 50(6):687-94. PubMed ID: 23557459
[TBL] [Abstract][Full Text] [Related]
4. Changes in total IgE plasma concentration measured at the third month during anti-IgE treatment predict future exacerbation rates in difficult-to-treat atopic asthma: a pilot study.
Dal Negro RW; Guerriero M; Micheletto C; Tognella S; Visconti M
J Asthma; 2011 Jun; 48(5):437-41. PubMed ID: 21599560
[TBL] [Abstract][Full Text] [Related]
5. [Disease modification and duration of omalizumab treatment in patients with severe allergic asthma].
Schreiber J; Kopp MV; Korn S; Taube C; Buhl R
Pneumologie; 2014 Mar; 68(3):187-92. PubMed ID: 24477463
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma.
Somerville L; Bardelas J; Viegas A; D'Andrea P; Blogg M; Peachey G
Curr Med Res Opin; 2014 Jan; 30(1):59-66. PubMed ID: 24028677
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of two commercial omalizumab/free IgE immunoassays: implications of use during therapy.
Baker DL; Peng K; Cheu M; Fischer SK
Curr Med Res Opin; 2014 May; 30(5):913-22. PubMed ID: 24354863
[TBL] [Abstract][Full Text] [Related]
8. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
D'Amato G; Piccolo A; Salzillo A; Noschese P; D'Amato M; Liccardi G
Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):225-31. PubMed ID: 19075985
[TBL] [Abstract][Full Text] [Related]
9. Monitoring of omalizumab therapy by measuring free IgE using a bedside immunoassay.
Steiss JO; Schmidt A; Rudloff S
Clin Lab; 2015; 61(1-2):31-7. PubMed ID: 25807635
[TBL] [Abstract][Full Text] [Related]
10. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey.
Deschildre A; Marguet C; Salleron J; Pin I; Rittié JL; Derelle J; Taam RA; Fayon M; Brouard J; Dubus JC; Siret D; Weiss L; Pouessel G; Beghin L; Just J
Eur Respir J; 2013 Nov; 42(5):1224-33. PubMed ID: 23520319
[TBL] [Abstract][Full Text] [Related]
11. Monitoring free serum IgE in severe asthma patients treated with omalizumab.
Korn S; Haasler I; Fliedner F; Becher G; Strohner P; Staatz A; Taube C; Buhl R
Respir Med; 2012 Nov; 106(11):1494-500. PubMed ID: 22884459
[TBL] [Abstract][Full Text] [Related]
12. [Omalizumab therapy in adolescents with severe allergic asthma - results of a post-marketing surveillance].
Klyucheva M; von Berg A; Gappa M; Suerbaum C; Berdel D
Pneumologie; 2013 Apr; 67(4):233-7. PubMed ID: 23576201
[TBL] [Abstract][Full Text] [Related]
13. Omalizumab (anti-IgE) therapy increases blood glucose levels in severe persistent allergic asthma patients with diabetes mellitus: 18 month follow-up.
Yalcin AD; Gorczynski RM; Cilli A; Strauss L
Clin Lab; 2014; 60(9):1561-4. PubMed ID: 25291953
[TBL] [Abstract][Full Text] [Related]
14. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy.
Odajima H; Ebisawa M; Nagakura T; Fujisawa T; Akasawa A; Ito K; Doi S; Yamaguchi K; Katsunuma T; Kurihara K; Kondo N; Sugai K; Nambu M; Hoshioka A; Yoshihara S; Sato N; Seko N; Nishima S
Allergol Int; 2015 Oct; 64(4):364-70. PubMed ID: 26433533
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effects of treatment with anti-IgE antibodies (Omalizumab) in a patient with severe asthma and negative skin-prick test results.
van den Berge M; Pauw RG; de Monchy JG; van Minnen CA; Postma DS; Kerstjens HA
Chest; 2011 Jan; 139(1):190-3. PubMed ID: 21208879
[TBL] [Abstract][Full Text] [Related]
16. Omalizumab protects against allergen- induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma.
Zielen S; Lieb A; De La Motte S; Wagner F; de Monchy J; Fuhr R; Munzu C; Koehne-Voss S; Rivière GJ; Kaiser G; Erpenbeck VJ
Int Arch Allergy Immunol; 2013; 160(1):102-10. PubMed ID: 22948442
[TBL] [Abstract][Full Text] [Related]
17. Plasmapheresis prior to omalizumab administration in a 15-year-old boy with severe asthma and very high IgE levels: sustained effect over 2 years.
Kerzel S; Zemlin M; Rogosch T; Ollert M; Renz H; Klaus G; Maier RF
Klin Padiatr; 2011 Nov; 223(6):356-9. PubMed ID: 22012605
[TBL] [Abstract][Full Text] [Related]
18. Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis.
Nayak A; Casale T; Miller SD; Condemi J; McAlary M; Fowler-Taylor A; Della Cioppa G; Gupta N
Allergy Asthma Proc; 2003; 24(5):323-9. PubMed ID: 14619332
[TBL] [Abstract][Full Text] [Related]
19. Changes of immunomodulatory cytokines associated with omalizumab therapy for severe persistent asthma.
Shimizu Y; Dobashi K; Fueki N; Fueki M; Okada T; Tomioka S; Makino S; Mori M
J Biol Regul Homeost Agents; 2011; 25(2):177-86. PubMed ID: 21880206
[TBL] [Abstract][Full Text] [Related]
20. Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table.
Kornmann O; Watz H; Fuhr R; Krug N; Erpenbeck VJ; Kaiser G
Pulm Pharmacol Ther; 2014 Aug; 28(2):149-53. PubMed ID: 24657236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]